Jentadueto™ tablets recommended for approval in the treatment of adults with Type 2 Diabetes in Europe
25 May 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company has received a positive opinion from the EMA...
List view / Grid view
25 May 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company has received a positive opinion from the EMA...
24 May 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Phase 3 study results for linagliptin 5 mg once-daily, which showed significant hemoglobin A1c (HbA1c or A1C) reduction of 0.88 percent compared to 0.24 percent in the placebo group (p=0.0002) at 24 weeks in black or African…
24 May 2012 | By H. Lundbeck A/S
H. Lundbeck A/S announced that the company has established a sponsored Level I ADR programme in the United States...
24 May 2012 | By AstraZeneca
New €224m funding to enable development of antibiotics for bacterial infections and drive unprecedented information sharing...
23 May 2012 | By Pfizer
Olivier will succeed David Simmons...
23 May 2012 | By Boehringer Ingelheim
1 Mission 1 Million announces its plans to support ongoing work in atrial fibrillation...
22 May 2012 | By Boehringer Ingelheim
Comprehensive Phase III UniTinA-asthma™ program ongoing...
22 May 2012 | By Pfizer
View webcast of a presentation by Pfizer’s oncology leadership team...
22 May 2012 | By Gerresheimer
Gerresheimer to present its entire portfolio of plastic pharmaceutical packaging products...
22 May 2012 | By Boehringer Ingelheim
1 Mission 1 Million launches petition and unique fundraising platform...
22 May 2012 | By Daiichi Sankyo
This agreement is designed to integrate the high-level cancer research technology...
22 May 2012 | By Eli Lilly and Company
Phase II trial used ambulatory blood pressure monitoring to evaluate blood pressure and heart rate for dulaglutide...
21 May 2012 | By Boehringer Ingelheim
Olodaterol significantly improved lung function (FEV 1) for at least 24 hours compared to placebo...
21 May 2012 | By Phenomenex Inc
Phenomenex Inc., introduces Phree Phospholipid Removal Plates for fast cleanup of plasma samples...
21 May 2012 | By Merck
The U.S. FDA approved a labeling update for ISENTRESS® Film-coated Tablets to include 156-week data from the STARTMRK study...